How is Novo Nordisk preparing for NovoSeven patent expiration?
NVO’s blockbuster rFVIIa drug, NovoSeven, goes off-patent in the US—its largest market—in 2011. NVO has a two-pronged approach to deal with this predicament:
2. A long-acting FVIIa analogue called NN7128 based on pegylation technology from NTEC, which is in phase-1 (#msg-21139054).
Clearly, both of these programs warrant close attention by GTC investors. However, these two drug candidates are FVIIa analogues, not FVIIa per se. Thus, they would seem to incur a higher regulatory risk than the FVIIa program from GTC and partner, LFB.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.